Submission of Un-Audited Standalone Financial Results for the Quarter ended as on June 30, 2026 and Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand ....

GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. To, Date: 14.08.2026 BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400001 Dear Sir/Madam Unit: Godavari Drugs Limited (Scrip Code: 530317) Sub: Outcome of Board Meeting held on 14.08.2026 With reference to the subject cited this is to inform the Exchange that the Board of Directors of Godavari Drugs Limited, at its Meeting held on Friday, 14th August, 2026, at 11:45 a.m. at the registered office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter ended 30.06.2026. (Attached) 2. Limited Review Report for the quarter ended 30.06.2026. (Attached) 3. Allotment of Equity Shares on conversion of 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) warrants into 7,86,690 (Seven Lakhs Eighty-Six Thousand Six Hundred and Ninety Only) Equity Shares at an issue price of Rs. 89/- each (including a premium of Rs. 10/- each), to “Promoters Category”, on preferential basis, upon receipt of balance amount aggregating to Rs. 5,25,11,557.5/- (Rupees Five Crores Twenty-Five Lakhs Eleven Thousand Five Hundred and Fifty-Seven and Paise Fifty Only) being 75% of the issue price per warrant, from the allottees pursuant to the exercise of their rights of conversion into equity shares in accordance with the provisions of SEBI (ICDR) Regulations, 2018 and list of allottees as mentioned in below annexures. (Details attached in Annexure - A) Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure-B. The meeting concluded at 12.30 p.m. This is for the information and records of the Exchange, please Thanking you. Yours faithfully, For Godavari Drugs Limited Venkatesh Achanta Company Secretary & Compliance Officer GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. ANNEXURE - A List of Proposed Allottees S No. Name of the Proposed Allottee Equity Shares to be Allotted upon conversion of Warrants Promoter Category 1. Ghanshyam Jaju 60,000.00 2. Kamala Jaju 1,00,000.00 3. Mohit Jaju 1,33,355.00 4. Priyanka Jaju 33334 5. Ieshir Jaju 66667 6. Mukund Kakani 156334 7. Sushma Kakani 141000 8. Tanushree Kakani 46000 9. Aksheit Kakani 50000 Total 7,86,690 GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. ANNEXURE – B Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 S No. Particulars Details 1. Type of securities proposed to be Equity Shares allotted on conversion of fully paid issued (viz. equity shares, Warrants. convertibles etc.); 2. Type of Issuance (further public Preferential allotment, on a private placement basis. Preferential Allotment offering, (Conversion of Warrants into Equity Shares). rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.) 3. Total number of securities Total number of securities allotted – 7,86,690 proposed to be issued or the total Total amount of securities allotted – amount for which the securities Rs.5,25,11,557.5/- (7,86,690 number of shares * will be issued (approximately) Rs. 66.75/- paid per share) 4. Names of the investors As per Annexure - A 5. Post allotment of securities - Post the conversion of warrants into equity shares, outcome of the subscription, issue the paid-up equity share capital of the Company has price / allotted price (in case of increased from Rs. 10,12,74,350/- (Rupees Ten convertibles), number of investors Crores Twelve Lakhs Seventy-Four Thousand Three Hundred and Fifty Only) consisting of 1,01,27,435 (One Crore One Lakhs Twenty-Seven Thousand Four Hundred and Thirty-Five Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 10,91,41,250/- (Rupees Ten Crores Ninety- One Lakhs Forty-One Thousand Two Hundred and Fifty Only) consisting of 1,09,14,125 (One Crore Nine Lakhs Fourteen Thousand One Hundred and Twenty-Five Only) Equity Shares of Rs. 10/- (Rupees Two Only) each. Allotment of 7,86,690 Equity Shares of Face Value of Rs. 10/- each fully paid up upon conversion of Warrants. 6. In case of convertibles - Exercise by conversion of 7,86,690 Warrants into intimation on conversion of 7,86,690 fully paid-up Equity Shares. securities or on lapse of the tenure of the instrument GODAVARI DRUGS LIMITED CIN : L24230TG1987PLC008016 Regd Office : 'Mayfair" S.P.Road, Secunderabad STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Rupees in Lakhs Sl. Quarter ended Year ended Particulars No. 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unudited) (Audited) (Unudited) (Audited) 1 Revenue from operations 2795.72 3316.31 2381.13 10580.81 2 Other Income 15.10 14.12 1.22 80.51 3 Total Revenue from operations (1+2) 2810.82 3330.43 2382.35 10661.32 4 Expenses (a) Cost of materials consumed 2614.88 3026.61 1798.93 8888.89 (b) Changes in inventories of finished goods & work-in-progress -634.45 -489.54 -85.41 -1139.13 (c) Employee benefits expense 147.68 132.05 135.67 569.66 (d) Depreciation & amortization expense 59.28 61.21 60.43 243.21 (e) Finance Costs 89.61 95.55 100.46 397.97 (f) Other Expenses 416.09 353.17 242.04 1229.93 Total expenses 2693.09 3179.05 2252.12 10190.53 5 Profit before exceptional Items and tax (3-4) 117.73 151.38 130.23 470.79 6 Exceptional items - 1 0.38 - 3 5.51 7 Profit before Tax (5+6) 117.73 161.76 130.23 506.30 8 Tax expense -6.82 -32.68 -26.17 -97.39 9 Net Profit for the period (7-8) 110.91 129.08 104.06 408.91 10 Other Comprehensive Income (i) Items that will not be reclassified to profit or loss - - - - (ii) Income tax relating to Items that will not be reclassified to profit or loss - - - - (iii) Items that will be reclassified to profit or loss - - - - (iv) Income tax relating to Items that will be reclassified to profit or loss - - - - Total Other Comprehensive Income (Net of Tax) - - - - 11 Total Comprehensive Income (9+10) 110.91 129.08 104.06 408.91 12 Paid-up equity share capital (Face Value Rs. 10/- per share) 1012.74 1012.74 753.05 1012.74 13 Other Equity as shown in the Audited Balance Sheet of the previous year - 6042.04 - 6042.04 14 Earnings per share (a) Basic 1.10 1.71 1.38 5.43 (b) Diluted 1.10 1.64 1.38 5.36 1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on August 14, 2026. 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. 3) EPS of Current Quarter is based on paid up capital of Rs. 1012.74 Lacs as against Rs. 753.05 Lacs as of 30.06.2025. 4) The format for un-audited quarterly results as prescribed in SEBI’s Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI’s Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS. 5) Corresponding figures in previsous year / period have been regrouped wherever considered necessary. For GODAVARI DRUGS LIMITED Mohit Jaju Place: Secunderabad Wholetime Director & CFO Date : 14.08.2026 DIN: 03405414 Plant: A6/2, MIDC, Nanded E oo , iO0o '.. 9o 9 (it , E ao } 1 o. ' . ( oc l)! aIo ,. EH oo( Ed PP , EJ N h. oo l\ , 0 !' := c oOE9o e! !o1 , ,k . o ) +Eo 6ro !hd ob Ea( Eoo l D !l Eu ooC6 et o C Ca( t, , ' b o h(u ELo ,00 2 c E(E b >ol Eo r )O l0 r a o({q( ,,, , iil sHer o. E *E €u t- E! !o c 0oC ooo ,, Te o ((( o )), too oo) !( ooooo , d E_ E o(Bo o ) E,Ed i ,t* : is\ r E Er S9E e " tlr T;H ib SY, E aE EJu J a E€T nP Et F s E E4.r *O0- d oE E id .. + l l6ocE 9( i r,, \ s€ b r Ec Eok l ! €r oo t Iq oo6 r a(, t o(oq Eoq ,,l 3Eq [Showing first 8,000 characters — download PDF for full document]